Stock events for Fate Therapeutics, Inc. (FATE)
Fate Therapeutics' stock price has fluctuated, reaching $1.48 as of March 7, 2026, with a 52-week range of $0.66 to $1.94. The stock has increased by 37.44% over the last six months and 34.03% year-to-date. Key events include the Fourth Quarter and Full Year 2025 Financial Results, where the company reported a Q4 2025 EPS of -$0.27 and revenue of $1.4 million, with a projected operating runway through year-end 2027. The Third Quarter 2025 Financial Results included authorization from UK and EU authorities to activate ex-US clinical trial sites for FT819. The Second Quarter 2025 Financial Results reported a quarterly loss of $0.29 per share, with revenues of $1.91 million. Pipeline progress and a strategic shift towards autoimmune diseases also impacted the stock.
Demand Seasonality affecting Fate Therapeutics, Inc.’s stock price
Information regarding specific demand seasonality for Fate Therapeutics, Inc.'s products and services is not readily available. Demand for its products, once commercialized, would likely be driven by disease prevalence, clinical efficacy, regulatory approvals, and market access rather than traditional seasonal patterns. The company's focus on off-the-shelf therapies aims to provide consistent and readily available treatments, which would inherently reduce any potential seasonality.
Overview of Fate Therapeutics, Inc.’s business
Fate Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing cellular immunotherapies for cancer and immune disorders, operating within the Biotechnology industry. The company utilizes an induced pluripotent stem cell (iPSC) platform to create off-the-shelf natural killer (NK) and T-cell product candidates. Key product candidates include FT819, an iPSC-derived CAR T-cell product candidate targeting CD19-positive lymphoid malignancies; FT522, an iPSC-derived CAR NK cell product candidate for B-cell Lymphoma and autoimmunity; FT836, a MICA/B-targeted off-the-shelf CAR T-cell therapy; FT825, a CAR T-cell program designed to treat solid tumors; and FT839, a CAR T-cell program for complex autoimmune diseases.
FATE’s Geographic footprint
Fate Therapeutics is headquartered in San Diego, California, and develops programmed cellular immunotherapies for cancer and immune disorders in the United States and internationally. Clinical trials are underway across North America and in select international sites, including the U.S., U.K., and EU.
FATE Corporate Image Assessment
Fate Therapeutics has a reputation as a leader in developing first-in-class cellular immunotherapies, particularly for its use of induced pluripotent stem cell (iPSC) technology. Early clinical results for FT819 have shown promising efficacy in systemic lupus erythematosus (SLE) patients. The successful outpatient treatment with FT819 enhances patient access and improves health system economics. Strategic collaborations with pharmaceutical partners, including Ono Pharmaceutical Co. Ltd., contribute positively. Potential concerns include the potential for FT819 to fail to demonstrate a clinical efficacy advantage, as well as concerns regarding safety, immunogenicity, and regulatory challenges.
Ownership
Fate Therapeutics has a mixed ownership structure including institutional, retail, and individual investors. Institutional investors hold a significant majority of the stock, with over 58% of the outstanding stock held by institutional money as of Q3 2025. Insiders own approximately 13.10% to 59.44% of the stock, while public companies and retail investors hold around 9.10% to 63.05%. Major institutional owners include Redmile Group, LLC, BlackRock, Inc., and The Vanguard Group, Inc. A notable individual owner (insider) is Amir Nashat.
